MOTS-c Research in June 2026: Two New Preclinical Studies

MOTS-c (short for "Mitochondrial Open Reading Frame of the 12S rRNA Type-c") is a mitochondrially encoded microprotein of 16 amino acids. The coding sequence sits within the mitochondrial 12S rRNA gene, which is why MOTS-c is counted among the mitochondrial-derived peptides (MDPs). In the literature, the substance is frequently described as a "mitokine", that is, a signaling molecule of mitochondrial origin that, in research models, is reported to act intracellularly, in a paracrine and in an endocrine manner (PMC9854231). MOTS-c was first described in 2015 in Cell Metabolism in the context of glucose metabolism and the insulin signaling pathway in animal models (ScienceDirect).

In June 2026, two new papers were published, which we classify neutrally in this update. Both are preclinical (animal and cell models) or summarizing (review). Statements about a benefit or an efficacy in humans cannot be derived from them.

Study 1: Review Article on MOTS-c in the Lung and Airways

The first paper is a review article from the Journal of Translational Medicine, published online ahead of print on 04.06.2026 (Amado CA et al., PMID 42243958, DOI 10.1186/s12967-026-08398-2). The author group is based at the Hospital Universitario Marques de Valdecilla, the Universidad de Cantabria and the IDIVAL in Santander, Spain.

A review summarizes the existing literature and does not generate its own experimental data. The paper classifies MOTS-c as a mitochondrial microprotein and describes, in the cited research, connections to metabolic homeostasis, oxidative and toxic stress, inflammatory processes, autophagy as well as mitochondrial function and immune response. These functional areas are named as research fields, not as proven effects of any application.

The thematic focus lies on respiratory medicine. According to the abstract, the authors report that circulating MOTS-c levels were measured lower in various forms of acute respiratory distress syndrome. In chronic airway conditions named in the paper as well (COPD, obstructive sleep apnea and asthma), the cited literature is said to have observed reduced MOTS-c concentrations, which the authors associate with mitochondrial dysfunction. Important for context: a lower concentration of a biomarker in a disease state says nothing about whether external administration influences a disease course. Correlation is not causation.

In addition, the review points to preclinical animal models in which exogenously administered MOTS-c was investigated in models of lung injury. The authors accordingly position MOTS-c as a possible biomarker candidate and as a potential research target in respiratory research. At the same time, they explicitly emphasize that well-designed translational and multicenter clinical studies are still required, and that findings in the area of lung carcinoma in particular need further validation. The paper itself describes the clinical translation as preliminary.

Study 2: MOTS-c in the Isolated Rat Heart (Ischemia-Reperfusion)

The second paper comes from Molecular Biology Reports, published on 02.06.2026 (Santhanam SS et al., PMID 42228044, 53(1):873, DOI 10.1007/s11033-026-12064-7). Title: "MOTS-c preserves mitochondrial subpopulation bioenergetics and genome integrity to attenuate cardiac ischemia reperfusion injury". It is an ex vivo animal study, that is, investigations on isolated organs outside the living animal.

The Langendorff system is an established laboratory method in which an isolated heart is perfused retrogradely via the aorta, so that function and metabolism can be measured under controlled conditions. A typical experimental sequence reproduces a phase without blood flow (ischemia) and a subsequent restoration of blood flow (reperfusion). A methodologically interesting point of this study is the separate examination of two mitochondrial subpopulations: subsarcolemmal mitochondria (beneath the cell membrane) and interfibrillar mitochondria (between the muscle fibers), which can differ in their properties.

According to the abstract, the authors report that MOTS-c in this model was associated with an improved mechanical recovery after ischemia as well as with reduced oxidative stress. The mitochondrial parameters, that is, enzyme activities, membrane potential, mtDNA copy number and gene expression, are said to have been partially preserved, with the result varying depending on the parameter. This exact wording is relevant: it is not a consistent normalization of all measured values, but rather a mixed, parameter-dependent picture in an isolated organ model.

The authors themselves cite as a limitation that the underlying signaling mechanisms need further validation. Added to this are the general limits of such a design: small group size (n = 6), only female animals, an ex vivo setup without an intact circulatory, nervous and immune system, as well as a single species. Results from isolated rat hearts cannot be transferred to the living organism, and certainly not to humans.

Context: What These Two Papers Have in Common

Both publications sit at the early end of the research pipeline. The airway review is a literature summary with a biomarker and target hypothesis; the cardiac study is a single-organ experiment in an animal model. In both cases, the authors explicitly state reservations and point to the need for further, methodologically robust research. A clinical benefit in humans is not proven by either paper.

In terms of content, the two topics are connected by a shared reference to mitochondrial biology: in the lung paper, a low MOTS-c level is associated with mitochondrial dysfunction; in the cardiac paper, mitochondrial bioenergetics and genome integrity are at the center of the measurements. This fits with the classification of MOTS-c as a mitochondrial microprotein, as also described in older mechanism reviews (PMC9854231). This thematic bracket is an observation about the direction of research, not a statement of effect.

Anyone who wants to continue following the state of MOTS-c research can find the primary sources directly via the PMIDs named above on PubMed.

Study Peptide in the Catalog

The peptide discussed in this article is offered by us as study material exclusively for laboratory research. It is not intended for human use.

MOTS-clongevity

Mitochondrial-derived signaling peptide (16 amino acids) that mimics the effects of exercise at the cellular level. Activates AMPK, improves glucose uptake, and enhances fat metabolism - a key tool in metabolic and longevity research.

Frequently Asked Questions

Note: All peptides offered here are intended exclusively for laboratory research (research use only). Not for human use, not for the diagnosis, treatment or prevention of diseases. Not for human consumption.